Welcome to our dedicated page for PetVivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PetVivo Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PetVivo Holdings's regulatory disclosures and financial reporting.
PetVivo Holdings, Inc. reported that its Chief Financial Officer, Garry N. Lowenthal, indirectly acquired 66,421 shares of common stock as a grant of restricted stock. The award was made to a corporation owned by him as compensation for his past performance at an implied price of $0.72 per share.
Following this grant, the filing shows 878,881 shares of common stock held indirectly through the corporation. This is a compensation-related, non-market transaction rather than an open-market purchase or sale.
Lai John reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. reported that a corporation owned by Chief Executive Officer John Lai received a grant of restricted common stock as compensation for his past performance. The award covers 66,421 shares of common stock at a stated value of $0.72 per share.
Following this grant, the corporation associated with Lai holds 2,306,913 shares of PetVivo common stock indirectly. This is a compensation-related stock award rather than an open-market purchase or sale, and reflects additional equity granted to an entity affiliated with the CEO.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Robert James Rudelius purchased 50,000 shares of restricted common stock in a private sale. On April 15, 2026, he bought these shares from another PetVivo shareholder at $0.40 per share, bringing his direct holdings to 403,392 common shares. He also reports indirect ownership of 21,000 common shares held by a corporation.
PetVivo Holdings, Inc. disclosed that A.L. Sarroff Fund, LLC, a ten percent owner, made open-market purchases of its common stock. The fund bought a total of 24,033 shares on March 23, 2026, including 23,033 shares at $0.68 and 1,000 shares at $0.7499 per share. Following these transactions, the fund directly holds 10,202,229 common shares, with Alan L. Sarroff deemed to beneficially own and exercise sole voting and dispositive power over these securities.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. director Robert James Rudelius received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service, valued at $0.74 per share on the grant date. Following this award, he directly holds 353,392 common shares. He also has an additional 21,000 shares reported as indirectly held through a corporation. This Form 4 reflects a compensation-related share grant rather than an open-market purchase or sale.
Ruben Joshua David reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Ruben Joshua David reported stock-based compensation grants. He received an aggregate annual grant of 46,332 restricted common shares for Board service, vesting in four installments: 8,832 shares for the pro-rated first quarter and 12,500 shares at the beginning of each subsequent quarter of service.
He also received a one-time grant of 7,500 restricted shares as compensation for prior Board service. Following these awards, he holds 53,832 common shares directly. These are compensation-related grants, not open-market purchases or sales.
PetVivo Holdings, Inc. director Diane M. Levitan reported an acquisition of 15,000 shares of common stock at $0.74 per share. The transaction is coded as a grant or award, meaning these shares were received as compensation rather than bought in the open market.
According to a footnote, this is a one-time grant of 15,000 restricted common shares as compensation for prior Board service. Following this award, Levitan directly owns 71,489 shares of PetVivo common stock.
Jasper Joseph William reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. director Jasper Joseph William received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service, valued at $0.74 per share on the grant date. Following this award, he directly holds 135,159 common shares, with an additional 2,000 shares held indirectly by his wife. This is a compensation-related equity grant, not an open-market purchase.
Costantino Robert J reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. reported that director Robert J. Costantino received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service. The grant, valued at $0.74 per share for reporting purposes, increases his direct holdings to 108,661 shares of common stock.
PetVivo Holdings, Inc. entered into a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received an initial $400,000 on March 13, 2026 and expects the remaining $600,000 on or before April 15, 2026.
The investor also received a purchase option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026, on the same terms. The transaction is a private offering to an accredited investor under Section 4(a)(2) and Regulation D, and the shares are restricted securities subject to Rule 144.